Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
EyeCyte logo — Partnering with esteemed institutions to pioneer new treatme...

EyeCyte

Partnering with esteemed institutions to pioneer new treatments for retinal diseases.

Founded 2005 United States La Jolla, United States 1 employees Series A Total: $3.00M Biotechnology, Health Care

General Information

Company Name EyeCyte
Founded Year 2005
Location United States La Jolla, United States +1
Employees 1
Industries Biotechnology, Health Care
Funding Stage Series A
Social

Get notified when EyeCyte moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About EyeCyte

EyeCyte is a biotechnology firm that partners with elite institutions like Pfizer's Bioinnovation and io therapeutics Center and The Scripps Research Institute to develop innovative treatments for retinal diseases. Since its inception in 2005, EyeCyte has maintained its focus on addressing neovascular and degenerative retinal conditions through cutting-edge therapeutics.

Headquartered in the United States, EyeCyte operates at the intersection of the Biotechnology and Health Care industries. The company's potential to revolutionize the treatment landscape in ophthalmology has attracted significant investor interest.

Notably, the last significant influx of capital was a $3.00M Series A investment on 23 June 2008, with Pfizer Venture Investments taking the lead. This strategic financial backing highlights investor confidence in EyeCyte's pioneering approach and collaborative efforts with academia and renowned institutions.

Taxonomy: Retinal Diseases, Therapeutics, Research, Partnerships, Innovation, Ophthalmology, Drug Development, Pfizer, Bioinnovation, Scripps Research Institute, Neovascular Disease, Degenerative Disease, Medical Collaboration, Clinical Trials

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 1 •••• •••• 23 Jun 2008

EyeCyte Alternatives & Competitors

EyeCyte vs
Gismo Therapeutics Inc.
Gismo Therapeutics Inc.

Pioneering advanced treatments for Alzheimer’s and Parkinson’s diseases since 2013.

Grant
6 employees
Biotechnology, Health Care
EyeCyte vs
IRB Barcelona
IRB Barcelona Spain

International biomedical #research center devoted to curing #cancer and other diseases linked to #ag...

479 employees
EyeCyte vs
Akebia Therapeutics
Akebia Therapeutics United States

We're focused on the development & commercialization of therapeutics for people living with kidney d...

Post Ipo Debt
268 employees
Biotechnology, Health Care

FAQ About EyeCyte

Partnering with esteemed institutions to pioneer new treatments for retinal diseases.
EyeCyte was founded in 2005.
EyeCyte is headquartered in La Jolla, United States.
EyeCyte operates in the following industries: Biotechnology, Health Care.
EyeCyte has approximately 1 employees.
EyeCyte has completed 1 funding round, raising a total of $3.00M. The latest funding stage is Series A.
Top alternatives and competitors to EyeCyte include Gismo Therapeutics Inc., IRB Barcelona, Akebia Therapeutics, ImmunoBiome Inc., Nitrase Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EyeCyte and Gismo Therapeutics Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors EyeCyte and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy